FindTrial
Sign In

BGF MDI 320/14.4/9.6 μg

DRUG6 trials

Sponsors

Pearl Therapeutics, Inc., AstraZeneca

Conditions

AsthmaCOPDCOPD (Chronic Obstructive Pulmonary Disease)

Phase 3

Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)
CompletedNCT02465567
Pearl Therapeutics, Inc.COPD
Start: 2015-06-30End: 2019-07-26Updated: 2021-02-02
A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)
CompletedNCT02497001
Pearl Therapeutics, Inc.COPD
Start: 2015-08-10End: 2018-01-05Updated: 2020-12-24
Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
CompletedNCT02536508
Pearl Therapeutics, Inc.COPD
Start: 2015-08-10End: 2017-09-12Updated: 2021-02-26
Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)
CompletedNCT04609878
AstraZenecaAsthma
Start: 2020-12-15End: 2025-03-21Updated: 2026-06-30
Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)
CompletedNCT04609904
AstraZenecaAsthma
Start: 2021-03-01End: 2025-03-20Updated: 2026-07-02
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
RecruitingNCT06283966
AstraZenecaCOPD (Chronic Obstructive Pulmonary Disease)
Start: 2024-02-21End: 2027-12-03Target: 5000Updated: 2026-08-26

Related Papers

Implementation of 2023 Canadian Thoracic Society Guidelines for Single-Inhaler Triple Therapy Could Reduce Exacerbation and Mortality Rates in COPD: PROMETHEUS Canada.
2026-03-30
Impact of Increased Single-Inhaler Triple Therapy Use in Appropriate Patients on Chronic Obstructive Pulmonary Disease Exacerbations, Mortality, and Medical Costs: PROMETHEUS Spain.
2025-11-21
Impact of Increased Use of Single-Inhaler Triple Therapies on COPD Exacerbation Rates, Mortality, and Total Costs: PROMETHEUS France.
2025-11-17
Frequent productive cough in COPD relates to exacerbation risk and treatment benefit from budesonide/glycopyrrolate/formoterol fumarate: a post hoc analysis of KRONOS.
2025-11-12
Short-acting β<sub>2</sub>-agonist use, exacerbation risk and triple therapy in COPD: <i>post hoc</i> analyses of ETHOS.
2025-11-01
Modeled reductions in COPD exacerbation rates, mortality, and related medical costs due to increased SITT adoption: PROMETHEUS Italy.
2025-10-28
Step up to triple therapy versus switch to dual bronchodilator therapy in patients with COPD on an inhaled corticosteroid/long-acting β2-agonist: post-hoc analyses of KRONOS
Respiratory Research2025-05-08
Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies for Patients with COPD and Phenotypic Features of Asthma: A Pooled Post Hoc Analysis of KRONOS and ETHOS
International Journal of COPD2024-12-012 citations
Effect of Triple Therapy on Cardiovascular and Severe Cardiopulmonary Events in Chronic Obstructive Pulmonary Disease: A <i>Post Hoc</i> Analysis of a Randomized, Double-Blind, Phase 3 Clinical Trial (ETHOS)
American Journal of Respiratory and Critical Care Medicine2024-08-3021 citations
Benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on lung function and exacerbations of COPD: a post-hoc analysis of the KRONOS study by blood eosinophil level and exacerbation history.
2024-08-053 citations
Associations between the EQ-5D-5L and exacerbations of chronic obstructive pulmonary disease in the ETHOS trial
Quality of Life Research2024-01-111 citations
Step up to ICS/LAMA/LABA vs switch to LAMA/LABA in patients with COPD on ICS/LABA: post hoc analysis of KRONOS
2023-09-091 citations
Mortality risk reduction with budesonide/glycopyrrolate/formoterol fumarate versus fluticasone furoate/umeclidinium/vilanterol in COPD: a matching-adjusted indirect comparison based on ETHOS and IMPACT.
2023-08-297 citations
PROMETHEUS: Long-Term Exacerbation and Mortality Benefits of Implementing Single-Inhaler Triple Therapy in the US COPD Population
Journal of health economics and outcomes research2023-01-247 citations
PROMETHEUS: Long-Term Exacerbation and Mortality Benefits of Implementing Single-Inhaler Triple Therapy in the US COPD Population
Journal of health economics and outcomes research2023-01-241 citations
Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOS.
2022-12-0618 citations
Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS Study.
2022-11-227 citations
Evaluating multiple eosinophil measurements when stepping up to ICS/LAMA/LABA triple therapy in patients with COPD: a post-hoc analysis of ETHOS
05.01 - Airway pharmacology and treatment2022-09-041 citations
Clinically important deterioration in patients with COPD: a post-hoc analysis of ETHOS
05.01 - Airway pharmacology and treatment2022-09-04
Relationship between risk, cumulative burden of exacerbations and mortality in patients with COPD: modelling analysis using data from the ETHOS study
BMC Medical Research Methodology2022-05-2511 citations

44 more papers not shown